Department of Urology, Sant'Andrea Hospital, Sapienza University, Rome, Italy -
Department of Urology, Sant'Andrea Hospital, Sapienza University, Rome, Italy.
Minerva Urol Nephrol. 2021 Oct;73(5):625-630. doi: 10.23736/S2724-6051.20.04088-6. Epub 2020 Nov 17.
Alpha-blockers (ABs) are considered the standard treatment after initial management of acute urinary retention (AUR). However, no data are available on the predictors of a successful trial without catheter (TWOC) in patients previously on treatment with ABs and 5alpha reductase inhibitors (5ARI). The aim of our study was to investigate prostate ultrasound parameters as predictors of TWOC outcome.
A consecutive series of patients, on treatment with ABs alone or in combination with 5ARI, experiencing AUR were prospectively enrolled. Clinical data (i.e., age, body mass index (BMI) and IPSS), urinary ultrasound features including hydronephrosis, prostate volume-TRUS, bladder wall thickness (BWT), intravesical prostatic protrusion more than 10mm (IPP≥10) were related to TWOC outcome performed seven days after AUR. A binary logistic regression analysis was computed to detect predictors of successful TWOC.
Overall,143 patients with a median age of 72 years (IQR 64-77) were enrolled. Seventy-mine patients (54%) with smaller prostate volume (59 [IQR 52-74] vs. 99 [IQR 74-125] mL, P=0.008) and a thinner BWT (5[IQR 4.8-5.2] vs. 5.2 [4.7-5.5] mm P=0.001) recovered voiding at TWOC. IPP≥10 was less common in patients with successful TWOC 11 (14%) vs. 33 (52%), P=0.001. On multivariate analysis, IPP<10mm (OR 6.10 [95%CI 2.61-14.20], P=0.001), lower IPSS (OR 0.95 [95% CI 0.89-0.99], P=0.045), smaller TRUS (OR 0.96 [95% CI 0.95-0.97], P=0.001), thinner BWT OR 1.23 (95%CI 0.73-0,92) P=0.001were the independent predictors of voiding recovery.
Patients receiving medical treatment for BPH and experiencing AUR still present a 54% probability of a successful TWOC. Ultrasound may help to identify patients with successful TWOC.
α受体阻滞剂(ABs)被认为是急性尿潴留(AUR)初始治疗后的标准治疗方法。然而,对于先前接受 AB 和 5α 还原酶抑制剂(5ARI)治疗的患者,尚无关于无导尿管试验(TWOC)成功的预测因素的数据。我们的研究目的是探讨前列腺超声参数作为 TWOC 结果的预测因素。
前瞻性纳入连续系列接受 AB 单独或联合 5ARI 治疗并发生 AUR 的患者。临床数据(即年龄、体重指数(BMI)和 IPSS)、尿超声特征,包括肾积水、前列腺体积-TRUS、膀胱壁厚度(BWT)、超过 10mm 的膀胱内前列腺突出(IPP≥10)与 AUR 后 7 天进行的 TWOC 结果相关。计算二元逻辑回归分析以检测 TWOC 成功的预测因素。
共有 143 名中位年龄为 72 岁(IQR 64-77)的患者入组。70 名患者(54%)的前列腺体积较小(59 [IQR 52-74] vs. 99 [IQR 74-125] mL,P=0.008),膀胱壁厚度较薄(5 [IQR 4.8-5.2] vs. 5.2 [4.7-5.5] mm,P=0.001),在 TWOC 时恢复排尿。IPP≥10 在 TWOC 成功的患者中较少见(11 [14%] vs. 33 [52%],P=0.001)。多变量分析显示,IPP<10mm(OR 6.10 [95%CI 2.61-14.20],P=0.001)、较低的 IPSS(OR 0.95 [95%CI 0.89-0.99],P=0.045)、较小的 TRUS(OR 0.96 [95%CI 0.95-0.97],P=0.001)、较薄的 BWT OR 1.23(95%CI 0.73-0.92],P=0.001)是排尿恢复的独立预测因素。
接受 BPH 药物治疗并发生 AUR 的患者仍有 54%的 TWOC 成功机会。超声可能有助于识别 TWOC 成功的患者。